Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024
LONDON, Dec. 16, 2014 /PRNewswire/ -- INTRODUCTION
Antibody drug conjugates (ADCs) are a new class of therapeutic agents, gaining increasing attention from both large and small pharmaceutical companies. Generally addressed as the marriage of an antibody with a toxic drug / chemotherapy drug, these conjugates are believed to be more efficient and effective in the treatment of a disease.
The ADC market is still in its infancy. At present, Adcetris and Kadcyla are the only two marketed drugs. However, there are several ADCs under development, with most of them being developed for oncological indication. Pharmaceutical companies are keen to add innovative molecules to their diminishing product pipelines and ADCs provide an attractive opportunity due to their novel nature.
Although the market now has presence of several large pharmaceutical companies, the technological capabilities for development of ADC still lies with a few technology providers. Seattle Genetics and ImmunoGen are amongst the pioneers in the field of ADC, with most pipeline ADCs using their technology. Most development to date has been carried under technology license agreements. However, we expect to see more co-development agreements in the future.
As more ADCs move from pipeline to the market, there is likely to be a further increase in investments in this area. Drug developers / venture capital firms are investing huge amount of money in biologics and it remains to be seen what proportion of this will be directed towards ADCs. The current market landscape will gradually evolve as large pharmaceutical companies look to gain competitive advantage in the ADC market. The future of the market is promising, though there are several challenges to meet.
SCOPE OF THE REPORT
The Antibody Drug Conjugates Market, 2014-2024 report provides an extensive study on this emerging field of therapeutics. The report covers various aspects, such as, advantages of antibody drug conjugates over traditional antibody therapeutics, the need for this new class of medicine, manufacturing challenges, key market drivers and upcoming opportunities.
One of the key objectives of this report is to understand the current and future state of the antibody drug conjugates market. This is done by analysing
- Products currently available in the market and those under development (both clinical / pre-clinical),
- Technology providers, and key cytotoxin, linker and conjugation technologies supporting the development of improved ADCs,
- Partnerships which have taken place over the last five years covering product co-development, technology licensing and co-marketing,
- Competitive landscape and inherent threats to growth in the short and long term,
- Development and sales potential based on target consumer segments, likely adoption rate and expected pricing.
The base year for the report is 2013; actual sales data has been presented for marketed ADCs during this year. The report provides short-mid term and long term market forecasts for the period 2014 - 2019 and 2019 - 2024, respectively. The research, analysis and insights presented in this report include potential sales of 11 marketed and pipeline ADCs; this analysis is backed by a deep understanding of key drivers behind the growth.
Owing to niche nature of the market, with most products in the pipeline, we have provided three market forecast scenarios to add robustness to our model. The conservative, base and optimistic scenarios represent three different tracks of industry evolution.
All actual figures have been sourced and analysed from publicly available information. The figures mentioned in this report are in USD, unless otherwise specified.
EXAMPLE HIGHLIGHTS
1. Driven by the sales of Adcetris and Kadcyla (the two drugs currently available commercially), the ADC market is likely to be worth more than USD 600 million in 2014.
2. About 45 molecules are currently in clinical development. Of these, approximately 25% are in Phase II or Phase III of development. As expected, the preclinical pipeline is also gradually expanding.
3. Most commonly used cytotoxins for ADCs under clinical development include auristatin, calicheamicin, maytansine and duocarmycin. Auristatin dominates the market and accounts for over 50% of ADCs in clinical development.
4. Roche, with 10 molecules in clinical development, has the most developed pipeline of ADCs. Relatively new entrants such as Oxford BioTherapeutics, Mersana Therapeutics, Abzena are likely to provide the necessary push (both in terms of technology and innovation).
5. Seattle Genetics and ImmunoGen are the two most active companies offering their proprietary ADC technologies to a large number of ADCs under development.
6. About 70%-80% of ADC manufacturing is currently outsourced. There are limited number of contract manufacturers with capabilities for development of linkers and cytotoxins. In addition, even fewer CMOs provide conjugation services for ADC.
7. Several technological developments have taken place in the recent past; more stable linkers and potent cytotoxins are likely to ensure that the next generation ADCs have improved safety/efficacy profile.
8. With around 7-10 new ADC commercial launches over the coming decade, we believe the overall market will be worth USD 10 billion annually by 2024.
RESEARCH METHODOLOGY
Most of the data presented in this report has been gathered by secondary research. We have also conducted interviews with experts in the area (academia, industry, medical practice and other associations) to solicit their opinions on emerging trends in the market. This is primarily useful for us to draw out our own opinion on how the market will shape up across different regions and drug segments. Where possible, the available data has been checked for accuracy from multiple sources of information.
The secondary sources of information include
- Annual reports
- Investor presentations
- SEC filings
- Industry databases
- News releases from company websites
- Government policy documents
- Other analysts' opinion reports
While the focus has been on forecasting the market over the coming ten years, the report also provides our independent view on various technological and non-commercial trends emerging in the industry. This opinion is solely based on our knowledge, research and understanding of the relevant market gathered from various secondary and primary sources of information.
CHAPTER OUTLINES
Chapter 2 presents an executive summary of the report. It offers a high level view on where the antibody drug conjugate market is headed in the mid-long term.
Chapter 3 provides a general introduction to the antibody drug conjugates. In this section we have discussed, in detail, the concept of ADC, its components, mechanism of action and advantages over traditional therapies.
Chapter 4 provides an overview of the ADC market. This chapter has information about all the ADC molecules in development (clinical or preclinical) along with their current phase of development, companies that are most active in the field of ADC and most common types of cytotoxin and linkers used for ADC development.
Chapter 5 presents our analysis on the ADC market for the upcoming decade. It includes detailed drug profiles and likely sales forecast for each of the drug currently in phase II or higher stage of development.
Chapter 6 discusses the current manufacturing challenges associated with ADCs. It also provides information about the leading contract manufacturers which are focused in this domain.
Chapter 7 provides insight to the recent developments and technological advancements. It includes a comprehensive list of partnerships, including the details of agreements, which have taken place between various pharmaceutical companies over the last few years.
Chapter 8 includes profiles of the key companies in the ADC market. Each company profile includes information such as financial performance, geographical presence, marketed / pipeline ADC drugs and recent developments.
Chapter 9 provides our analysis of the strengths, weaknesses, opportunities and threats in the ADC market, capturing the key elements likely to influence future growth.
Chapter 10 is a collection of interview transcripts; these discussions have helped us in forming a better understanding of the key market dynamics, competitive landscape and the likely future trends in the market.
Chapter 11 summarises the overall report. In this chapter, we have provided a recap of the key takeaways and our independent opinion based on the research and analysis described in previous chapters.
Chapter 12 is an appendix, which provides tabulated data and numbers for all the figures provided in the report.
Chapter 13 is an appendix, which lists down all the companies and organisations involved in the ADC market.
Download the full report: https://www.reportbuyer.com/product/2280919/
About Reportbuyer
Reportbuyer is a leading industry intelligence solution that provides all market research reports from top publishers
http://www.reportbuyer.com
For more information:
Sarah Smith
Research Advisor at Reportbuyer.com
Email: [email protected]
Tel: +44 208 816 85 48
Website: www.reportbuyer.com
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/antibody-drug-conjugates-market-2nd-edition-2014---2024-300010652.html
SOURCE ReportBuyer
Share this article